Alkermes reports positive Phase 1b data for ADHD drug ALKS 7290
Alkermes said the orexin 2 receptor agonist showed dose-dependent symptom improvements in adults with ADHD, with a Phase 2 trial now enrolling and data expected in 2027.
SEC filing
Latest
7 stories
Monday, September 21
Wednesday, September 16
Alkermes announces Anne C. Whitaker's appointment to board via press release
The company confirmed the September 14 board appointment in a September 16 statement that included executive comments and details on Whitaker's background.
SEC filing
Wednesday, August 12
Alkermes amends credit facility, cuts interest rate spreads
Alkermes signed an amendment on August 12, 2026 to its February 2026 credit agreement, lowering the interest rate spreads on its term loan A and term loan B facilities.
SEC filing
Monday, August 10
Alkermes registers Phase 2 trial of ALKS 7290 for adult ADHD
Tuesday, August 4
Alkermes registers expanded access program for pediatric LYBALVI patients
Monday, August 3
Alkermes expands Blair Jackson's role to President and CEO, sets pay and board seat
The board added the President title, approved compensation and equity awards, and named Jackson a director, all effective August 1, 2026.
SEC filing
Tuesday, July 28
Alkermes names Blair Jackson CEO, effective August 1, as pipeline milestones near
Richard Pops steps down as CEO to remain Chairman while Alkermes awaits ADHD data for ALKS 7290 and year-end results from its alixorexton hypersomnia study.
SEC filing